TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02404259

Intervention type: DRUG
Group type: OTHER
Intervention: TDF (Tenofovir)

Intervention type: DRUG
Group type: OTHER
Intervention: TDF (Tenofovir)

Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz

Intervention type: DRUG
Group type: OTHER
Intervention: lopinavir/ritonavir, atazanavir/ritonavir
Study: NCT01692275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care + Chiropractic Care
Description: Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Care Only
Description: Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
Study: NCT02600832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AABM Training
Description: The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Sham training is identical to AABM training, except pictures are presented randomly in both formats.
Study: NCT01294579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
Study: NCT00531752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654746
Description: Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654746
Description: Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
Study: NCT04261790

Intervention type: DRUG
Group type: OTHER
Intervention: Ocrelizumab
Description: Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
Study: NCT00401375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
Study: NCT02849561

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic hypothermia
Description: With a mattress at 4°C to reach a central temperature at 33,5°C.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic hypothermia
Description: With a mattress at 4°C to reach a central temperature at 33,5°C.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation
Description: Constant volume 6 ml/kg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation
Description: Constant volume 6 ml/kg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pupillary light reflex surveillance
Description: With Neurolight® device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pupillary light reflex surveillance
Description: With Neurolight® device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Doppler
Description: Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Doppler
Description: Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
Study: NCT03268044

Intervention type: OTHER
Intervention: Hospital admission and surgery
Description: Hospital admission and noncardiac surgery

Intervention type: OTHER
Intervention: Hospital admission and surgery
Description: Hospital admission and noncardiac surgery
Study: NCT04899700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linked Color Imaging
Description: Inspection of the postpolypectomy scar will be made with Linked Color Imaging

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Linked Color Imaging
Description: Inspection of the postpolypectomy scar will be made with Linked Color Imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White light endoscopy
Description: Inspection of the postpolypectomy scar will be made with White light Endoscopy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White light endoscopy
Description: Inspection of the postpolypectomy scar will be made with White light Endoscopy
Study: NCT00579852

Intervention type: PROCEDURE
Intervention: CT Scan
Description: Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
Study: NCT01967537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Gallium DOTATATE
Description: Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio-guided surgery
Description: Using 68Gallium DOTATATE
Study: NCT01251107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg/m2 IV day 8 during cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: 100 mg/m2 po from day 1 to 7 during cycles 1 to 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m2 po from day 1 to 14 during cycles 1 to 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 25 mg/m2 iv on days 1 and 15 in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: 10 mg/m2 iv on days 1 and 15 in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: 6 mg/m2 iv on days 1 and 15 in each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 375 mg/m2 iv on days 1 and 15 in each cycle
Study: NCT03362424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: Mesenchymal stem cells applies at the end of rotator cuff repair in de active group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Rotator cuff repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair
Description: Rotator cuff repair
Study: NCT00350142

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D pancreatic protocol CT scan
Description: Patients will undergo this imaging procedure prior to treatment for planning purposes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG PET scan
Description: Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
Study: NCT05297942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expansion of Abbreviations and Acronyms
Description: Expansion of Abbreviations and Acronyms
Study: NCT03371446

Intervention type: GENETIC
Intervention: oral epithelial cells obtained by rinsing with 3% sucrose
Description: rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
Study: NCT03241953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
Study: NCT02827864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sequentially apply tDCS and MT
Description: The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: apply tDCS concurrently
Description: Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: MT with sham tDCS
Description: The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
Study: NCT03054376

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization
Description: Full length cast of one leg R/L randomized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization
Description: Full length cast of one leg R/L randomized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training with non immobilized leg
Description: Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training with both legs
Description: Exercise training will be conducted regularly on a cycle ergometer during a four week period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training with both legs
Description: Exercise training will be conducted regularly on a cycle ergometer during a four week period
Study: NCT03028571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
Study: NCT01509196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP0901 / Lipidilsupra
Description: HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HIP0901 / Lipidilsupra
Description: HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
Study: NCT00947336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin + Synbiotic
Description: Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norfloxacin + Placebo
Description: Norfloxacin 400 mg once daily with placebo
Study: NCT00562354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 13vPnC for both stratum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 13vPnC for both stratum
Study: NCT03458208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage®
Description: Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition
Study: NCT02516241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study: NCT02864290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1235
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1235
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1235
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1235
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1235
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1235
Description: intravenous (IV) infusion
Study: NCT05063058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molecular guided therapy
Description: Biomarker-driven therapy according to recommandations of the precision oncology tumor board including MEK Inhibitors (Trametinib 2 mg/d, Selumetinib 75 mg 2/d), MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d), RAS Inhibitor (Sorafenib 400 mg 2/d), Cell cycle Inhibitor (Palbociclib 125 mg/d) and Checkpoint Inhibitor (Nivolumab 240 mg every 2 weeks).
Study: NCT02374528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pressure bolster dressing
Description: This method is traditional used in skin grafting wound.
Study: NCT04033497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
Study: NCT06654570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravaginal estrogen during adjuvant letrozole
Description: Postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks. Gynecologic examination and symptom screening were conducted at baseline and after 12 weeks. Serum E2 levels were analyzed at baseline, and at two, four, eight, and 12 weeks. E2 levels were measured using both a routine liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and a highly sensitive (hsE2-MS) LC-MS/MS method.
Study: NCT01104311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aggressive BP lowering
Description: adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modest blood pressure lowering
Description: adjust the amount and number of antihypertensive drugs
Study: NCT03524729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rocker bottom shoe
Description: Walking shoe with a anterior posterior rocker sole.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle foot orthosis
Description: Dynamic carbon fiber ankle brace.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard walking shoe
Description: Standard walking shoe (control shoe) with no rocker sole.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard walking shoe
Description: Standard walking shoe (control shoe) with no rocker sole.
Study: NCT03632473

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal evoked potentials (mmEP)
Description: combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal evoked potentials (mmEP)
Description: combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal evoked potentials (mmEP)
Description: combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal evoked potentials (mmEP)
Description: combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
Study: NCT03458208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage®
Description: Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition
Study: NCT01026831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-Free Tafluprost
Description: One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: timolol
Description: One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
Study: NCT01708109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no measures taken to clear bile ductus
Description: biliary calculus remain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clearance of bile ductus
Description: biliary calculus removed at surgery
Study: NCT04249687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Description: neuromodulator

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02611388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: 2/10HZ Electric stimulation was given through electrode attached to specific acupoints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: 10/50HZ Electric stimulation was given through electrode attached to specific acupoints

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: fake stimulation
Description: Patients were only attached electrodes without electric current